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Pheromone biosynthesis-activating neuropeptide (PBAN) and pyrokinins belong to a family of
insect peptide hormones that have a common FXPRLamide C-terminal ending. The G-protein-cou-
pled receptors (GPCRs) for this peptide family were ﬁrst identiﬁed from a moth and Drosophila with
sequence similarity to neuromedin U receptors from vertebrates. We have characterized the PBAN-
receptor (PBAN-R or PR) active binding domains using chimeric GPCRs and proposed that extracel-
lular loop 3 is critical for ligand selection. Here, we characterized the 3rd extracellular domain of
PBAN-R through site-directed point mutations. Results are discussed in context of the structural fea-
tures required for receptor activation using receptor activation experiments and in silico computa-
tional modeling. This research will help in characterizing these receptors towards a goal of ﬁnding
agonists and/or antagonists for PBAN/pyrokinin receptors.
Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.1. Introduction
Neuropeptides are the largest group of neurohormones pro-
duced in the central or peripheral nervous tissues, and released
for intercellular communication for various physiological and
behavioral regulatory events during development and reproduc-
tion in animals. A number of peptide families have been identiﬁed
and classiﬁed based on their functional and/or structural charac-
teristics in insects [1]. Pheromone biosynthesis-activating neuro-
peptide (PBAN)/pyrokinin family of peptides have been identiﬁed
and characterized with a conserved C-terminal pentapeptide
(FXPRLamide) which represents the minimal sequence required
for activity [2,3]. Insects from a variety of Orders and even a crus-
tacean have peptides with the FXPRLamide motif, although not all
insects regulate pheromone biosynthesis using this peptide. PBAN-
like peptides found in other insects have other functions including
contraction of hindgut muscles (pyrokinin activity), melanization
in Lepidoptera larvae, induction of embryonic diapause in the silk-
worm (diapause hormone), acceleration of puparium formation in
ﬂies, and termination of pupal diapause in heliothine moths [2,4].
PBAN is produced in the subesophageal ganglion and released
into the hemolymph where it stimulates pheromone biosynthesis
in the pheromone gland of moths. Since the Drosophila melanogas-lf of the Federation of European Bi
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i), rjurenka@iastate.edu (R.A.ter genome was completed, 44 genes coding G-protein-coupled
receptors (GPCRs) were classiﬁed [5]. Four of these were identiﬁed
as belonging to the neuromedin U-like family of GPCRs in
vertebrates and the ligands were identiﬁed as belonging to the
FXPRLamide peptide family [6]. Subsequently, the PBAN-receptor
(PBAN-R or PR) was identiﬁed from pheromone glands of Heli-
coverpa zea female moths [7], and from other moths [8–10].
Knowledge about PBAN-R structure is required to understand
its functional interaction with PBAN and for the development of
antagonists and agonists [11]. The structural analysis of GPCRs
for hormones and neurotransmitters is very difﬁcult because they
are low in abundance and embedded in the cell membrane. The
ﬁrst solved crystal structure of an intact GPCR from bovine rhodop-
sin has been used to model the PBAN-R [12]. Recently the crystal
structures have been determined for human adrenergic and aden-
osine GPCRs [13–15]. Based on the identiﬁed and crystallized
GPCRs and their involvement in many human diseases, computer
based-homology modeling methods are now popular [16–18]. An-
other method that has been utilized is creating chimeric receptors
from distant or closely related GPCRs to help understand how
these receptors transduce agonist binding into receptor activation
[19–21].
The primary sequences of peptide hormone GPCRs in insects
have only recently been identiﬁed and little information is avail-
able about their structures. Testing of chimeric receptors created,
from distant but related GPCRs, is a useful approach to understand
how speciﬁc receptors transduce agonist binding into receptor
activation [20]. We were especially interested in the role ofochemical Societies.
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vation of the receptor. We have characterized for the ﬁrst time the
active binding domains of an invertebrate GPCR using chimeric
receptors where the three extracellular loops or N-terminus of
the PBAN-R was swapped with the corresponding sequence in a
related Drosophila GPCR [19]. We found that extracellular loop 3
(ECL-3) is critical to determine which ligand, PBAN or pyrokinin
1 (PK1) activates the receptor [19]. In the present study, we
focused on the speciﬁc 3rd extracellular domain of PBAN-R
through point mutations and predicted conformational structures
using in silico modeling.
2. Materials and methods
2.1. Materials
Synthetic H. zea PBAN and leucopyrokinin (LPK: PETSFTPR-NH2)
were purchased from Bachem (San Carlos, CA). Fluo-4/acetoxy-
methyl ester (AM) was purchased from Molecular Probes.
2.2. Cloning of HezPBAN-receptor
Cloning procedures for HezPBAN-R were followed as described
previously [7]. Synthesized cDNA frommRNA extracted from pher-
omone gland of 1–3-day old H. zea female adults was ampliﬁed
with a primer set shown in Fig. 1, carrying NotI and XbaI linker
in the N- and C-terminal ends, respectively. All cloned receptors
and mutants were sequenced and conﬁrmed before transfecting
Sf9 cells.
2.3. Site-directed point mutagenesis of the 3rd extracellular loop of the
PBAN-R (PR)
The methodology for creating point mutations by PCR ampliﬁ-
cation is shown in Fig. 1. The mutation site E297, S300 or F303 in
PBAN-R as indicated in Fig. 2 was replaced with A297, A300, or
A303 by PCR ampliﬁcation with PBAN-R as template using primer
sets in Fig. 1. PBANR-A1 was ampliﬁed by PR-A1F and PR-R to pro-Fig. 1. Outline of method for creating mutant GPCRSs from HezPBAN-R using a PCR bas
indicate point-mutation sites contained nucleotides (in bold) for alanine in each primers,
PCR with designed primer sets (lower). Primers, PR-F and PR-R were tailed with NotI andduce a partial C-terminal sequence containing A297 to stop codon,
and using primer set: PR-F and PR-A1R to produce an N-terminal
sequence containing ATG to A297 of PBAN-R. Then, the full length
PBANR-A1 was produced by a second round of PCR using primer
set: PR-F and PR-R using the two ampliﬁed PCR products from
above reactions as templates. The other two mutated receptors,
PBANR-A300 and PBAN-A303 were produced with primer sets: PR-
A2F and PR-A2R, and PR-A3F and PR-A3R, by PCR method de-
scribed above and previously [19].
2.4. Single-cell calcium imaging
Approximately 2–2.5  104 cells (200 ll per well) from suspen-
sion culture were seeded into a 96-well cell-culture plate with
black walls and a clear bottom and incubated overnight at 28 C.
Each well was incubated with Fluo-4/AM for 20–25 min and chal-
lenged with peptide and then ionomycin to obtain a relative ﬂuo-
rescence intensity as described in the previous study [7,19]. The
results were analyzed by non-parametric analysis as ranks (Fisher
PLSD, ANOVA) using Statview 5.0 software.
2.5. Protein structure prediction and modeling
Amino acid sequences of HezPBAN-R or mutated GPCRs were
submitted to SWISS-MODEL using the Swiss-PdbViewer [22], and
requested homology model from the GPCR template library. The
web-based Automated Mode of Swiss-Model program provided
the homology modeling of HezPBAN-R or mutated GPCRs using
the human adenosine A2A receptor (3eml.pdb) as a base template
[23,24]. Our previous model [25] used rhodopsin as the template
because, at the time, it was the only crystal 3D structure available
for GPCRs. Currently the adenosine and adrenergic crystal struc-
tures have been solved [13–15]. The Automated Mode of Swiss-
Model chose to utilize the human adenosine A2A receptor as a
homology model for each mutant HezPBAN-R. This may not neces-
sarily be the best overall model, but provides a prediction about
what will happen in the third extracellular loop with speciﬁc
mutations. The 3-D structures of PBAN-R and mutant GPCRs PDBed cloning strategy as described in detail in Section 2. White intervals in the ECL-3
PR-AF and PR-AR. Mutated PBAN-Rs were produced by several additional rounds of
XbaI sites (underlined) that were used for vector insertion. ECL: extracellular loop.
Fig. 2. The schematic diagram of PBAN-receptor, and sites of point mutation. Three site-directed mutants of the PBAN-R (PR) 3rd extracellular loop (ECL) were created by
exchanging alanine (A, in bold) with glutamate (E), serine (S), and phenylalanine (F, underlined) of the original PBAN-R (upper). Three protein kinase C phosphorylation sites
(*) and one cAMP- or -cGMP-dependent protein kinase phosphorylation site (**) were predicted in the intracellular domains. The schematic diagram is adapted from Choi
et al. [19].
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(www.rasmol.org) or Swiss-PdbViewer. We also used a web-base
server, PredictProtein (www.prodictprotein.org), to predict 3-D
modeling and phosphorylation sites. The view of GPCRs was edited
by an Adobe Photoshop software ver. 9.
3. Results and discussion
In previous studies [19,25] the extracellular domains of the
moth PBAN-R were exchanged with Drosophila PK1-R (DrmPK1-
R), and tested for binding activity. The results indicated that all
extracellular domains to some degree are involved in ligand bind-
ing and/or receptor activation. The most interesting ﬁnding indi-
cated that the ECL-3 sequence confers selectivity toward peptide
ligands as either PBAN-like or diapause hormone-like. These re-
sults indicate that several amino acids in the PBAN ECL-3 could
be involved in recognizing ligands, and site-directed mutagenesis
of these amino acids might interfere with binding activity and
receptor activation. Recently, a similar study on the subtype 1 neu-
rotensin receptor revealed that ECL-3 is critical for neurotensin
binding and receptor activation [26]. We conducted site-directed
mutagenesis of the ECL-3 of the PBAN-R to investigate binding
activity and we also predicted their structural models using an in
silico computational program.
3.1. Phosphorylation sites for protein kinases
Protein kinase phosphorylation sites can be involved in cellular
signal transduction after activation of GPCRs. The Swiss-Model
program predicted a cAMP- and cGMP-dependent protein kinase
phosphorylation site at serine244 (S244) based on the consensus se-
quence pattern, K241-K242-L243-S244 on the 3rd intra-cellular loop.
Usually, a consensus sequence pattern of S or T-X-R or -K, predicts
a protein kinase C (PKC) site [27], and two PKC sites on the 3rdintracellular loop and one on the intracellular-C-terminus of HezP-
BAN-R were located (Fig. 2). These sites could be important for sig-
nal transduction from the cell surface to intracellular side after
receptor activation.
3.2. Functional expression and binding activity of mutant PBAN-
receptors (PRs)
Three site-directed point mutations of PBAN-R were designed
by comparing the HezPBAN ECL-3 sequence with the 3rd extracel-
lular loop of DrmPK1-R. The targeted amino acids were chosen
based on functional groups which are charged or uncharged and/
or polar and aromatic groups that could potentially interact with
the peptide ligands. Mutated receptors were constructed by
replacement with an alanine (A) residue on ECL-3 of the HezP-
BAN-R and PBAN and LPK binding activity was measured in vitro.
3.2.1. PR-A297
The relative ﬂorescence intensity of PBANR-A297 mutation was
not changed compared to PBAN-R binding PBAN or LPK at
300 nM (Fig. 3). The results indicate that this amino acid change
did not increase or decrease binding activity of PBAN or LPK. It also
indicates that the negative charged amino acid (E297) exchanged
with a non-polar residue (A297) did not affect the conformation
of PBAN-R ECL-3. The results are supported by in silico PR-A297
modeling which was exactly the same as the original PR 3-D struc-
ture (Fig. 4).
3.2.2. PR-A300
The polar uncharged residue serine (S300) on the 3rd loop was
exchanged with alanine (A300) (Fig. 2). The relative ﬂuorescence
intensity decreased by approximately half compared to the native
PBAN-R or PBANR-A297 after challenge with PBAN (Fig. 3). This re-
duced activity indicates that the site mutation could interfere with
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Fig. 3. Relative ﬂorescence intensity of activated HezPBAN-R (HezPR) and three
mutant receptors expressed in sf9 cells after PBAN or leucopyrokinin (LPK) peptide
challenge (300 nM). Values represent the mean + S.E.M. of three replications of at
least 10 cells per replication.
Fig. 4. Comparison of 3-D models of HezPBAN-R (HezPR) and site-directed point
mutants of PR-A297, PR-A300 and PR-A303 using Swiss-Model. The ECL-3 of the
PBAN-receptors are indicated with an arrow head. The model of PR-A297 is exactly
same as the original PR and PR-A296.
M.-Y. Choi, R.A. Jurenka / FEBS Letters 584 (2010) 1212–1216 1215the proper PBAN binding causing a conformationally changed ECL-
3. The in silico ECL-3 structural model of PBANR-A300 also indicated
differences from the original loop of the native HezPBAN-R (Fig. 4).
The residue S300 of ECL-3 could be an important position to main-
tain a correct structural conformation of the extracellular domain.
This conformational change may not only be residue S300 speciﬁc
but could also change other amino acid conformations.
3.2.3. PR-A303
The 3rd site-directed mutation exchanged A303 with the aro-
matic residue phenylalanine (F303) and a reduced ﬂorescence
intensity was observed similar to PR-A300 after challenge with
PBAN or LPK (Figs. 2 and 3). The activation of PR-A303 was relatively
higher with PBAN and lower with LPK than the activation of
PBANR-A300, but they were not signiﬁcantly different (Fig. 3). An
in silico model of PR-A303 was proposed and indicates that deleting
the aromatic residue F303 and replacement with A303 resulted in a
conformational change (Fig. 4). It is unclear if this interaction is
phenylalanine speciﬁc or if other functional groups underwent a
conformational change.
3.2.4. Proposed models from in silico site-direct mutagenesis on ECL-3
of PBAN-R
The amino acids from 293 to 303 on the ECL-3 of PBAN-R were
replaced by A, then submitted into the automated mode of Swiss-
Model program to predict models. The conformational model of
the point mutation of A296 exchanged with L296 was well preserved
and exactly matched the native PBAN-R and PR-A297 (Fig. 4). There-
fore, the activation of the mutant PR-A296 would be expected to be
similar to that of the native PBAN-R or PBANR-A297. Both amino
acids, L and A, have similar non-polar and aliphatic functional
groups, therefore, A replacement would theoretically not affect a
conformational change. Similarly, the residues, G293, K294, S295 or
H298 replaced with A resulted in exactly the same structural model
which was well matched to PR-A300 ECL-3 (Figs. 4 and 5). There-
fore, PBAN binding activity from those mutations is expected tobe similar as PR-A300 (Fig. 3). From the modeling and binding re-
sults of the mutated receptors, those residues could play an impor-
tant role to maintain a proper ECL-3 binding site. The in silico
mutants-A299(P299), -A301(D301), or -A302(T302) suggested a slightly
different model of ECL-3 structure for each mutation (Fig. 5), and
PBAN binding activities of these receptors could be reduced.
The chimeric receptors using two insect GPCRs [19] and their
matching computational molecular models [25] have been used
to identify the functional binding sites of the PBAN-R. Speciﬁc chi-
mera or mutant construction, transfection and expression into
cells, then analysis of binding activity is needed. In case of low
activity, a green ﬂuorescence protein tag can be used to verify that
the GPCR protein is expressed properly or was not on the cell sur-
face. This experimental procedure for each chimeric receptor or
mutant is time consuming work. In the present study, a site-direc-
ted in silico mutagenesis approach could prove advantageous to
save time. Predicted structural models and expected binding activ-
ity could be correlated for a speciﬁc extracellular functional do-
main. Speciﬁc GPCRs with the most critical conformational
changed residue(s) based on structural modeling could be con-
structed and expressed to determine ligand activation levels. This
Fig. 5. Putative models of site-directed point mutations of PBAN-receptor (PR)
replaced with A (alanine) from amino acid position 293, 294, 295, 298, 299, 301, or
302 in the 3rd extracellular loop (ECL-3) using Swiss-Model program. Each mutant
ECL-3 is indicated with an arrow head. PR-A293, -A294, -A295, and -A298 are
identical to the structure of PR-A300 as shown in Fig 3.
1216 M.-Y. Choi, R.A. Jurenka / FEBS Letters 584 (2010) 1212–1216research will help in the modeling of these receptors towards a
goal of ﬁnding and screening agonist and/or antagonist for PBAN/
pyrokinin receptors, an important class of receptors in insects.
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